A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas

doi:10.2147/DDDT.S79475

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas
	Zhang, YH; Sun, XL; Huang, M; Ke, YQ; Wang, JH; Liu, X; Ke, YQ (reprint author), Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China.
刊名	DRUG DESIGN DEVELOPMENT AND THERAPY
	2015
卷号	9 页码:2947-2959
关键词	bispecific immunotoxin human mesenchymal stem cells ephrin A1 VEGF(165) malignant glioma
ISSN号	1177-8881
DOI	10.2147/DDDT.S79475
文献子类	Article
英文摘要	Background: In previous years, immunotoxins have been shown to be a greatly promising therapeutic tool for brain malignancies, such as gliomas. Human mesenchymal stem cells (hMSCs) exhibit tropism to tumor tissue. However, the effect of bispecific immunotoxins in malignant gliomas is still unknown. The aim of this study was to investigate the function of bispecific immunotoxins in human malignant gliomas. Materials and methods: In the present study, the bispecific immunotoxin VEGF(165)-ephrin A1-PE38KDEL was established using deoxyribonucleic acid shuffling and cloning techniques. The VEGF(165)-ephrin A1-PE38KDEL was delivered by hMSCs to mouse malignant gliomas. The effects of the bispecific immunotoxins on glioma-derived blood vessels and vasculogenic mimicry to elucidate the molecular mechanisms underlying the antitumorigenic effects of immunotoxins were examined in vivo. Results: In vitro, transfected hMSCs significantly inhibited the cell viability of gliomas cell lines U87 and U251 in a dose-dependent manner compared with untransfected hMSCs (P<0.01). In vivo, the intratumoral injection of engineered hMSCs was effective at inhibiting tumor growth in a malignant glioma tumor model. Conclusion: The bispecific immunotoxin secreted from hMSCs acts as a novel strategy for improving treatment options for malignant gliomas in the clinic.
学科主题	Pharmacology & Pharmacy
出版地	ALBANY
资助项目	国家自然科学基金项目
项目编号	Nature Science Foundation of Guangdong [S2012010009088] ; National Nature Science Foundation of China [81272806]
语种	英语
WOS记录号	WOS:000356190100001
资助机构	NSFC
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/178518]
专题	第一临床医学院_期刊论文
通讯作者	Ke, YQ (reprint author), Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China.
推荐引用方式 GB/T 7714	Zhang, YH,Sun, XL,Huang, M,et al. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas[J]. DRUG DESIGN DEVELOPMENT AND THERAPY,2015,9:2947-2959.
APA	Zhang, YH.,Sun, XL.,Huang, M.,Ke, YQ.,Wang, JH.,...&Ke, YQ .(2015).A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.DRUG DESIGN DEVELOPMENT AND THERAPY,9,2947-2959.
MLA	Zhang, YH,et al."A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas".DRUG DESIGN DEVELOPMENT AND THERAPY 9(2015):2947-2959.